• Addex Therapeutics raised gross proceeds of USD 2.8 million through its at-the-market offering agreement with H.C. Wainwright.
• Sold 437,869 ADSs representing 52,544,280 shares under the equity distribution program.
• Cash runway extended to the fourth quarter of 2027 following the sales.
• Outstanding shares excluding treasury shares rose to 210,292,217; issued shares stayed at 218,654,496.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005744), on August 26, 2026, and is solely responsible for the information contained therein.